Targeting HER receptors in cancer

Related Experiment Video

Updated: May 18, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Alberto Ocaña1, Atanasio Pandiella

  • 1Instituto de Biologia Molecular y Celular del Cancer-CIC, Campus Miguel de Unamuno, 37007- Salamanca, Spain.

Current Pharmaceutical Design
|September 15, 2012
PubMed

Insights

This review explains how human epidermal growth factor receptor (HER) activation drives cancer and discusses targeted therapies. It covers current treatments, future developments, and strategies to overcome resistance to anti-HER therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) are crucial in development; their dysregulation links to diseases like cancer and diabetes.
  • The ERBB/HER family of receptors is implicated in various cancers, including breast, gastric, colorectal, lung, and head and neck tumors.
  • HER receptor activation involves receptor-receptor interactions, ligand binding, overexpression, or molecular alterations, with HER2 being a key example in breast cancer.

Purpose of the Study:

  • To elucidate the biological mechanisms of HER receptor activation.
  • To provide a foundation for understanding how to target HER receptors therapeutically in cancer.
  • To review current and future strategies for targeting HER receptors and overcoming resistance.

Main Methods:

  • Literature review of biological bases governing HER receptor activation.
  • Analysis of current therapeutic options targeting HER receptors, including antibodies and kinase inhibitors.
  • Examination of clinical applications, future developments, and resistance mechanisms.

Main Results:

  • Detailed explanation of HER receptor activation pathways.
  • Overview of existing anti-HER therapies (antibodies, small molecule inhibitors).
  • Discussion of clinical efficacy, emerging treatments, and resistance patterns.

Conclusions:

  • Targeting HER receptors is a validated strategy in oncology.
  • Understanding activation mechanisms is key to developing effective therapies.
  • Addressing resistance is crucial for improving patient outcomes in HER-targeted cancer treatment.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...